Tech Center 1600 • Art Units: 1658
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17785772 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Final Rejection | Merck Sharp & Dohme LLC |
| 17487661 | BIODEGRADABLE MICRONEEDLE SYSTEM WITH SUSTAINED RELEASE | Non-Final OA | University of Connecticut |
| 18000004 | ANTIBODY-BOUND NANOPARTICLES | Non-Final OA | University of Washington |
| 17310119 | PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR | Final Rejection | Baylor College of Medicine |
| 17598717 | RECOMBINANT SILK BASED PRODUCTS AND METHODS OF PREPARING THE SAME | Final Rejection | EVOLVED BY NATURE, INC. |
| 17612047 | Variant Single-Chain Insulin Analogues | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 17999235 | COMPOSITIONS AND METHODS FOR PREVENTION OF CORONAVIRUS INFECTION | Non-Final OA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17998404 | POLYPEPTIDE ALBUMIN NANOPARTICLE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | SUZHOU INSTITUTE OF NANO-TECH AND NANO-BIONICS (SINANO) , CHINESE ACADEMY OF SCIENCES |
| 17778034 | OLIGOPEPTIDE HAVING BLOOD PRESSURE REDUCING EFFECT, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | South China Agricultural University |
| 18124252 | SYNTHETIC PEPTIDES FOR DISSOLVING TAU INCLUSIONS | Final Rejection | The Trustees of Princeton University |
| 18447414 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | Non-Final OA | Peptilogics, Inc. |
| 17920637 | PREPARATION METHOD AND APPLICATION OF INTERFERING PEPTIDE TARGETING SARS-CoV-2 N PROTEIN | Non-Final OA | SOOCHOW UNIVERSITY |
| 17607714 | METHOD FOR PRODUCTION OF LIPOSOMES | Non-Final OA | UNIVERSIDADE DO MINHO |
| 17747360 | PEPTIDE SCYREPROCIN OF SCYLLA PARAMAMOSAIN AND METHOD THEREOF | Final Rejection | Xiamen University |
| 18020082 | PEPTIDE SELECTIVELY BINDING TO CANCER CELL-DERIVED EXOSOME, AND USES THEREOF | Final Rejection | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | Final Rejection | HANMI PHARM. CO., LTD |
| 17996549 | IL4/IL13 RECEPTOR MOLECULES FOR VETERINARY USE | Non-Final OA | Elanco US Inc. |
| 17796950 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Administrators of the Tulane Educational Fund |
| 18019382 | ANTIMICROBIAL PEPTIDOMIMETICS | Non-Final OA | UNIVERSITÄT ZÜRICH |
| 18018481 | CONJUGATED HEPCIDIN MIMETICS | Non-Final OA | Protagonist Therapeutics, Inc. |
| 17795331 | TREATMENT OF PANX1 ASSOCIATES DISEASES | Final Rejection | NURITAS LIMITED |
| 17635796 | PEPTIDES FOR TREATING MUSCLE ATROPHY | Non-Final OA | NURITAS LIMITED |
| 18298798 | NANOPARTICLE IN WHICH ANTIBACTERIAL PEPTIDE IS ENCAPSULATED WITH CHITOSAN AND USE THEREOF | Final Rejection | NATIONAL MARINE BIODIVERSITY INSTITUTE OF KOREA |
| 18031063 | ANNEXIN A5 COMPOSITIONS AND METHODS | Non-Final OA | London Health Sciences Centre Research Inc. |
| 18178143 | Short Proline Rich Lipopeptide Potentiates Minocycline and Rifampicin Against Multidrug- and Extensively Drug-Resistant Pseudomonas Aeruginosa | Non-Final OA | Polyamyna Nanotech Inc. |
| 17596095 | RECOMBINANT FAP BINDING PROTEINS AND THEIR USE | Non-Final OA | MOLECULAR PARTNERS AG |
| 17997852 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Non-Final OA | NEULAND LABORATORIES LIMITED |
| 17920517 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND USES THEREOF | Final Rejection | Rein Therapeutics, Inc. |
| 17996126 | LONG ACTING GLUCAGON RECEPTOR SELECTIVE PEPTIDES AND METHODS OF USE | Non-Final OA | i2o Therapeutics, Inc. |
| 18046138 | BRI2 BRICHOS DOMAIN FOR DELIVERY OF PROTEINS INTO CNS NEURONS | Non-Final OA | ALPHABETA AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy